Table 2.
Anthelmintic | ERP in days (mean) | Reference |
---|---|---|
Ivermectin (IVM) | 63 | Borgsteede et al. (1993) |
IVM | 35 to >56 | von Samson-Himmelstjerna et al. (2007) |
IVM | 42 | McFarlane et al. (2010) |
IVM | ≥42 | Larsen et al. (2011) |
IVM | 49–112 | Zak et al. (2017) |
IVM | 28 to >42 | Rosanowski et al. (2017) |
IVM | 28–49 | Molena et al. (2018) |
IVM | 42 | Relf et al. (2014) |
IVM | 28–42a | (van Doorn et al., 2014) |
IVM | 28 to >56 | Geurden et al. (2014) |
IVM | 90–150 | Sanna et al. (2016) |
IVM | 56–70 | Daniels and Proudman (2016) |
IVM | ≥42a | Kooyman et al. (2016) |
IVM | 42 | Beasley et al. (2017) |
IVM | 49–63 | Butler et al. (2021) |
IVM | 42 | Johnson and Biddle (2021) |
Moxidectin (MOX) | >84 | Holm-Martin et al. (2005) |
MOX | 35 | Rossano et al. (2010) |
MOX | 42–84 | Tzelos et al. (2017) |
MOX | 42–63 | Relf et al. (2014) |
MOX | 42a | (van Doorn et al., 2014) |
MOX | 42 | Geurden et al. (2014) |
MOX | >150 | Sanna et al. (2016) |
MOX | 77–91 | Daniels and Proudman (2016) |
MOX | 42 to ≥56a | Kooyman et al. (2016) |
MOX | 84 | Beasley et al. (2017) |
MOX | 35 | Abbas et al. (2021) |
MOX | 84 | Johnson and Biddle (2021) |
Papers with known shortened ERP prior to study.